Tumor necrosis factor-α polymorphisms and expression in Guillain-Barré syndrome

Human Immunology

Volumn 71, Issue 9, 2010, Pages 905-910

  Prasad, Kashi N ^a   Nyati, Kishan K ^a   Verma, Avantika ^a   Rizwan, Arshi ^a   Paliwal, Vimal K ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Gene polymorphism; Guillain Barr syndrome; Immunopathogenesis; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENOTYPE; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSORY NEUROPATHY;

ADULT; FEMALE; GENE FREQUENCY; GENOTYPE; GUILLAIN-BARRE SYNDROME; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956012788     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2010.06.013     Document Type: Article

References (41)

1. Griffin J.W., Li C.Y., Ho T.W., Tian M., Gao C.Y., Xue P., et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996, 39:17-28.
2. Nachamkin I., Allos B.M., Ho T.W. Campylobacter jejuni infection and the association with Guillain-Barré syndrome. Campylobacter 2000, American Society for Microbiology, Washington, DC. I. Nachamkin, M.J. Blaser (Eds.).
3. Ho T.W., Mishu B., Li C.Y., Gao C.Y., Cornblath D.R., Griffin J.W., et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995, 118:597-605.
4. Csurhes P.A., Sullivan A.A., Green K., Pender M.P., McCombe P.A. T cell reactivity to P0;P2; PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2005, 76:1431-1439.
5. Wanschitz J., Maier H., Lassmann H., Budka H., Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome. Brain 2003, 126:2034-2042.
6. Sharief M.K., McLean B., Thompson E.J. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993, 33:591-596.
7. Zhu W., Mix E., Zhu J. Inflammation and proinflammatory cytokine production, but no demyelination of facial nerves, in experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 2003, 140:97-101.
8. Gherardi R.K., Chouaïb S., Malapert D., Bélec L., Intrator L., Degos J.D. Early weight loss and high serum tumor necrosis factor-alpha levels in polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes syndrome. Ann Neurol 1994, 35:501-505.
9. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988, 23:339-346.
10. Redford E.J., Hall S.M., Smith K.J. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor. Brain 1995, 118:869-878.
11. Wilson A.G., di Giovine F.S., Blakemore A.I., Duff G.W. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992, 1:353.
12. Herrmann S.M., Ricard S., Nicaud V., Mallet C., Arveiler D., Evans A., et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur J Clin Invest 1998, 28:59-66.
13. Uglialoro A.M., Turbay D., Pesavento P.A., Delgado J.C., McKenzie F.E., Gribben J.G., et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 1998, 52:359-367.
14. Jacob C.O., Fronek Z., Lewis G.D., Koo M., Hansen J.A., McDevitt H.O. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: Relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci U S A 1990, 87:1233-1237.
15. Sariban E., Imamura K., Luebbers R., Kufe D. Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest 1988, 81:1506-1510.
16. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997, 94:3195-3199.
17. van Heel D.A., Udalova I.A., De Silva A.P., McGovern D.P., Kinouchi Y., Hull J., et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. Hum Mol Genet 2002, 11:1281-1289.
18. Zhang J., Dong H., Li B., Li C.Y., Guo L. Association of tumor necrosis factor polymorphisms with Guillain-Barré syndrome. Eur Neurol 2007, 58:21-25.
19. Geleijns K., Emonts M., Laman J.D., van Rijs W., van Doorn P.A., Hermans P.W., Jacobs B.C. Genetic polymorphisms of macrophage-mediators in Guillain-Barré syndrome. J Neuroimmunol 2007, 190:127-130.
20. Ma J.J., Nishimura M., Mine H., Kuroki S., Nukina M., Ohta M., et al. Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. Ann Neurol 1998, 44:815-818.
21. Waldron-Lynch F., Adams C., Amos C., Zhu D.K., McDermott M.F., Shanahan F., et al. Tumour necrosis factor 5' promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun 2001, 2:82-87.
22. Noguchi E., Yokouchi Y., Shibasaki M., Inudou M., Nakahara S., Nogami T., et al. Association between TNFa polymorphism and the development of asthma in the Japanese population. Am J Respir Crit Care Med 2002, 166:43-46.
23. Asbury A.K., Cornblath D.R. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990, 27:S21-S24.
24. Hadden R.D., Cornblath D.R., Hughes R.A. Electrophysiological classification of Guillain-Barré syndrome: Clinical associations and outcome. Plasma exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998, 44:780-788.
25. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
26. Nonomura N., Tokizane T., Nakayama M., Inoue H., Nishimura K., Muramatsu M., Okuyama A. Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients. Int J Urol 2006, 13:971-976.
27. Soga Y., Nishimura F., Ohyama H., Maeda H., Takashiba S., Murayama Y. Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 2003, 30:524-531.
28. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
29. Radhakrishnan V.V., Sumi M.G., Reuben S., Mathai A., Nair M.D. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. Acta Neurol Scand 2004, 109:71-74.
30. Hartung H.P., Hughes R.A., Taylor W.A., Heininger K., Reiners K., Toyka K.V. T cell activation in Guillain-Barré syndrome and in MS: Elevated serum levels of soluble IL-2 receptors. Neurology 1990, 40:215-218.
31. Dahle C., Ekerfelt C., Vrethem M., Samuelsson M., Ernerudh J., helper T. Type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. J Neurol Sci 1997, 153:54-60.
32. Stoll G., Jung S., Jander S., van der Meide P., Hartung H.P. Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 1993, 45:175-182.
33. Zhu J., Mix E., Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 1998, 84:40-52.
34. Exley A.R., Smith N., Winer J.B. Tumour necrosis factor-alpha and other cytokines in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1994, 57:1118-1120.
35. Brettschneider J., Petzold A., Süssmuth S., Tumani H. Cerebrospinal fluid biomarkers in Guillain-Barré syndrome - where do we stand?. J Neurol 2009, 256:3-12.
36. Sivieri S., Ferrarini A.M., Lolli F., Matà S., Pinto F., Tavolato B., Gallo P. Cytokine pattern in the cerebrospinal fluid from patients with GBS and CIDP. J Neurol Sci 1997, 147:93-95.
37. Press R., Ozenci V., Kouwenhoven M., Link H. Non-T(H)1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 2002, 58:476-478.
38. Lv K., Chen R., Cai Q., Fang M., Sun S. Effects of a single nucleotide polymorphism on the expression of human tumor necrosis factor-alpha. Scand J Immunol 2006, 64:164-169.
39. Louis E., Franchimont D., Piron A., Gevaert Y., Schaaf-Lafontaine N., Roland S., et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998, 113:401-406.
40. Maxwell J.R., Potter C., Hyrich K.L., Barton A., Worthington J., Isaacs J.D., et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008, 17:3532-3538.
41. Fowler E.V., Eri R., Hume G., Johnstone S., Pandeya N., Lincoln D., et al. TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J Med Genet 2005, 42:523-528.